| Intravenous conivaptan. | |
| | |
MedLine Citation:
|
PMID: 18828645 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
*Conivaptan is an arginine vasopressin V1A and V2 receptor antagonist. The intravenous formulation is approved in the US for use in the treatment of euvolemic and hypervolemic hyponatremia. Conivaptan produces a dose-dependent electrolyte-sparing aquaresis (solute-free water excretion), increasing serum sodium levels. *In a randomized, double-blind, parallel-group, placebo-controlled, multicenter trial in adults with euvolemic or hypervolemic hyponatremia, the area under the serum sodium concentration-time curve over a 4-day treatment duration (primary endpoint) was significantly greater in intravenous conivaptan 40 mg/day recipients than in placebo recipients. *The total time during treatment that patients had serum sodium levels > or = 4 mEq/L above baseline was significantly longer in intravenous conivaptan than placebo recipients. In conivaptan recipients, an increase in serum sodium levels of > or = 4 mEq/L above baseline was achieved approximately 1 day after the first dose of the drug. *In addition, the mean change from baseline in free water clearance and effective water clearance over the first day of treatment was significantly greater with intravenous conivaptan than with placebo. *Given the nature of the treatment, the tolerability profile for intravenous conivaptan was generally acceptable in patients with hyponatremia. The most common adverse events were injection related (e.g. injection-site phlebitis), hypotension, and pyrexia. |
| | |
Authors:
|
Marit D Moen; Gillian M Keating |
Related Documents
:
|
21941475 - Experiencing art: the influence of expertise and painting abstraction level. 21850285 - A report from the 164th american psychiatric association (may 14-18, 2011 - honolulu, h... 22085095 - On the incidence of illegal abortion. 21330895 - The mock trial: a collaborative interdisciplinary approach to understanding legal and e... 19922205 - Errata. 11028235 - A scandal in salzburg or freud's surreptitious role in the 1908 abraham-jung dispute. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of cardiovascular drugs : drugs, devices, and other interventions Volume: 8 ISSN: 1175-3277 ISO Abbreviation: Am J Cardiovasc Drugs Publication Date: 2008 |
Date Detail:
|
Created Date: 2008-10-02 Completed Date: 2009-01-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100967755 Medline TA: Am J Cardiovasc Drugs Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 341-8; discussion 349 Citation Subset: IM |
Affiliation:
|
Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Benzazepines / administration & dosage*, adverse effects, pharmacokinetics Clinical Trials as Topic Dose-Response Relationship, Drug Humans Hyponatremia / drug therapy* Infusions, Intravenous Receptors, Vasopressin / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Benzazepines; 0/Receptors, Vasopressin; 0/conivaptan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Thrombocytopenia associated with antithrombotic therapy in patients with cardiovascular diseases: di...
Next Document: Learning to EXHALE: don't catch the flu this season!